Fate Therapeutics (FATE) Tops Q3 EPS by 3c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.86), $0.03 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $14.98 million versus the consensus estimate of $15.71 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Proto Labs (PRLB) PT Raised to $91 at Benchmark on Meeting and Exceeding Previous Target
• Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting